Introduction
============

*Streptococcus pneumoniae* is the major cause of life-threatening diseases such as pneumonia, otitis media, bacteremia and meningitis worldwide. Despite causing numerous clinical diseases, only a few virulence factors i.e. surface proteins, cell wall and capsule components have so far been described ([@B1]).

The cell wall of *S. pneumoniae* is composed of peptidoglycan with teichoic acid attached to N-acetylmuramic acid. Structurally, teichoic acid is composed of N-acetyl-d-galactosaminyl repeats, which commonly carry two phosphocholine residues. Moreover, there are ribitol phosphate and tetrasaccharide containing d-glucose and 2-acetamido-4-amino-2, 4, 6-trideoxy-d-galactose residues. Pneumococci cannot synthesize choline required for the formation of these structures, and it is therefore considered as an essential growth factor ([@B2]). Additionally, choline residues of teichoic acid are thought to have an essential role in pneumococcal biofilm formation ([@B3]). Choline binding proteins (CBPs), a family of surface proteins, contain a number of short choline-binding repeats (consisting of 2 to 10 repeats of a 20-amino-acid sequence), which bind to choline in the teichoic and lipoteichoic acids in the pneumococcal cell wall ([@B4]).

These surface-exposed proteins play a crucial role in *Pneumococcus* pathogenesis and are therefore desirable as new vaccine candidates instead of pneumococcal polysaccharide vaccines as previously described ([@B5]). Currently, about twenty choline-binding proteins have been documented, and this number is constantly increasing. Several members of this protein family have been studied, and some unique and common properties have been characterized for each of them. CbpA, a well-characterized choline binding protein, has an elongated structure with α-helical N-terminal region consisting of three distinct domains ([@B6]). This protein is involved in development of invasive disease and has a highly protective nature following vaccination ([@B7], [@B8]).

The results of DNA sequencing showed that the *cbpA* coding locus exists in all tested virulent strains of *S. pneumoniae*. However, the locus encodes CBPs with allelic variation in the anchor region, which results in different sizes and compositions ([@B9]). Other CBPs have also been characterized, and there is valuable information about their structure and properties ([@B10]). CbpD, CbpG, CbpF and CbpE are important choline binding proteins with enzymatic functions. CbpD, CbpE as well as LytA, B and C may be associated with hydrolase activity. There is obvious homology in their C-terminus where the choline-binding domains are located ([@B11]). CbpG is a serine protease with multifunctional properties in different forms. This protein cleaves extracellular matrix of the host in the cell-attached or secreted forms, and shows adhesive properties in the cell-attached form. It is also required for pneumococcal virulence, colonization and invasive disease and may be as an effective vaccine ([@B12]). Recently, several choline-binding proteins such as CbpM, CbpK, CbpL and CbpF have also been reported, and their properties have been predicted bioinformatically ([@B13]). CbpM is a short 14.4 KDa cho-line binding protein with 129 amino acids. To the best of our knowledge, there is a limited data about this choline binding protein.

In this study, we attempted to clone and express CbpM and demonstrate its interaction with plasma proteins and patients' sera.

Materials and Methods
=====================

Recombinant protein expression and purification
-----------------------------------------------

Genomic DNA from overnight-cultured *S. pneumoniae* (ATCC 49619) was extracted using QIAamp DNA Mini Kit (Qiagen, Germany) according to the manufacturer's instructions. The coding sequence of *cbp*M gene was amplified by PCR using the following specific forward and reverse primers carrying *Nde*-I and *Xho*-I restriction sites (underlined), respectively: F-5′- GCGCGC[CATATG]{.ul}GTAAAAAGACGTATAAGGAGAGGG-3′R: 5′- GCGCGC[CTCGAG]{.ul}ACGCACCCATTCACCATTATCATT-3′.

The resulting PCR product was digested with *Nde*-1 and *Xho*-1 restriction enzymes (Fermentase, Germany) and ligated into a *p*ET21a vector (Novagen, USA), which was pre-digested with the same enzymes. The ligation product was transformed into competent *Eschericia coli* DH5α cells, and recombinant colonies were screened by colony PCR using T7 primers. Finally, recombinant vector was sequenced after extraction to confirm the correct gene composition.

The recombinant protein was expressed in BL21 (DE3) host strain. Briefly, a colony of *E. coli* harboring constructed *p*ET21a was cultured on Luria-Bertani (LB) broth containing ampicillin (1μg/ml)) and incubated at 37 °C for 24 h while shaking. After this step, 200 μl of overnight culture was transferred into 5 mL of LB broth containing ampicillin (1 μg/ml) at 37 °C. When OD~600~ reached 0.6, isopropyl-β-D-thiogalactopyranoside (IPTG) (Sigma-Aldric, USA) was added to a final concentration of 1mM, and the cells were grown for 4 hours at 37 °C with continuous shaking. Similar cultures were used as control without the addition of IPTG. The bacterial cultures were transferred to centrifuge bottles and centrifuged at 5000g for 5 min. The pellet and supernatant were transferred to separate tubes, and the cell pellets were resuspended in 100 μl SDS-PAGE sample buffer and were subjected to 12.5% SDS-PAGE. Purification of recombinant protein was performed using affinity chromatography under denaturing condition. Briefly, after overexpression of BL21 (DE3) in 250 ml LB broth (Merck, Germany) containing ampicillin, the bacterial culture was centrifuged at 5000g for 5 minutes and plate lysed by sonication on ice in solution buffer (300 mM NaCl, 50 mM NaH2PO4, pH:8.0). Following centrifugation at 5000g for 5 minutes, supernatant was removed and precipitate solved in 5ml of urea 8M. The Ni-NTA resin (Qiagen, Germany) was packed into a column and the denatured lysate gently loaded. Column was washed three times with washing buffers (urea 8M with different pHs (7, 6.3 and 5.9) and the eluted fractions (urea 8M pH: 4.5) were dialyzed overnight against Phosphate-buffered saline (PBS). Quality of recombinant protein purification was evaluated by 12.5% SDS-PAGE method.

Confirmation of recombinant protein
-----------------------------------

The purified recombinant protein was electrophoresed on 12.5 % SDS-PAGE and was subsequently transferred to nitrocellulose membrane (Millipore, Bedford, USA). The membrane was blocked with 3% blocking buffer (PBS-1X containing 3% skim milk) at room temperature for 12 h and washed three times with washing buffer (PBS-1X containing 0.05% Tween 20). The nitrocellulose membrane was incubated with His-tag monoclonal antibody conjugated to HRP(Thermo Fisher Scientific Inc., USA) at 1:1000 dilution for 1h at 25°C and was washed three times with washing buffer. Finally, the membrane was treated with 3, 3-diaminobenzidine solution (Sigma-Aldrich, USA) for ∼3 min.

Interaction with plasma proteins
--------------------------------

In order to determine unambiguously whether CbpM is a plasma binding protein, purified CbpM (10 μg/ml) was electrophoresed on a 12.5% SDS-PAGE gel as described above, transferred to a nitrocellulose membrane (Millipore, Bedford, USA) by electroblotting, and blocked in TBS-T containing 3% (wt/vol) Skim milk (Merck, Germany). Then, biotinylated fibrinogen and fibronectin were used to probe the membrane (at a concentration of 2 μg/ml in washing buffer). The bound ligands were detected by alkaline phosphatase-conjugated streptavidin (Sigma-Aldrich, USA) at a dilution of 1:1000 and NBT/BCIP solution (Roche, Germany). Pneumococcal Spr1754 and staphylococcal ScaA proteins were used as negative and positive controls, respectively ([@B14]).

Reactivity of serum antibody with recombinant CbpM protein by ELISA
-------------------------------------------------------------------

Ten serum samples were obtained from patients with pneumococcal pneumonia hospitalized at Loghman-Hakim hospital affiliated to Shahid Beheshti University of Medical Sciences (2014--2015). Recombinant CbpM protein (10 μg/well) was adsorbed in PBS 1x buffer into 96-well polystyrene plates (Greinerbio-one, Fricken-hausen, Germany) overnight at 4°C. The plate was then washed three times with washing buffer containing 0.05 Tween 20 and blocked with blocking buffer containing 4% skim milk for 1h at room temperature. The plate was washed three times with washing buffer and sera added into wells at dilutions of 1:10, 1:100 and 1:250 and incubated for 1h at room temperature. After wash step, goat anti-human Ig peroxidase-conjugated (Cytomatin Gene Co, Isfahan, Iran) with a dilution of 1:4000 was added into microplate well and incubated for 30 minutes. Finally, TMB (Cytomatin Gene Co, Isfahan, Iran) as substrate was added into wells and the reaction was stopped after 10 min by the addition of 50 μl of 1N H2SO4. Two serum samples obtained from healthy individuals were used as negative controls.

Results
=======

Cloning, expression and purification of cbpM gene
-------------------------------------------------

The expected amplicon was obtained after PCR assay, and was successfully ligated in *p*ET21a vector following digestion with *Nde*-1 and *Xho*-1 restriction enzymes. The accuracy of cloned target was confirmed after double digestion and sequencing stages. The sequence of *cbpM* was submitted to GenBank (Sequence ID: KJ668600.1), and the result of double digestion is presented in [Fig. 1.](#F1){ref-type="fig"}

![Electrophoresis of digested recombinant vector and PCR product on agarose gel (1%). Lane 1 and 2 digested vectors with *Xho*-1 and *Nde*-1 restriction enzymes, respectively; lane 3: cbpM PCR product (387bp) and lane 4 is double digest of recombinant vector. Lane 5: DNA Marker (1Kb)](IJPH-45-1610-g001){#F1}

As shown in [Fig. 2](#F2){ref-type="fig"}, recombinant protein was successfully expressed in BL21 (DE3) expression host, and the insoluble protein was obtained.

![Identification and analysis of the recombinant protein by SDS-PAGE (12.5%). Lane M: Protein molecular weight marker: 14.4--116 kDa; Lane 1: whole bacteria before induction; Lane 2 to Lane 4: whole bacteria 1, 4 and 8h after induction; Lane 5: Pellet of the sonicated lysate, 6: Supernatant of the sonicated lysate](IJPH-45-1610-g002){#F2}

The best expression condition was obtained at 4h at 37°C after IPTG addition. The recombinant protein was purified with high purity using Ni-NTA column ([Fig. 3](#F3){ref-type="fig"}). The His-tagged recombinant CbpM protein was confirmed using Anti-His-antibody ([Fig. 4](#F4){ref-type="fig"}).

![SDS-PAGE analysis of purified recombinant protein. Lane M: protein molecular weight marker14.4-116Kda, lane T0: un-induced BL21DE3, lane T4: induced BL21DE3, lane B: binding stage, lane W1: first wash, laneW5: fifth wash, lanes E1, E5 and E6 are elution stages](IJPH-45-1610-g003){#F3}

![Western blot analysis of purified recombinant protein CbpM. Lane M: Protein size marker (Sinaclon, Iran); lane 1: Recombinant protein western blotting with His-Tag monoclonal antibody](IJPH-45-1610-g004){#F4}

Interaction of recombinant CbpM protein with fibronectin and fibrinogen
-----------------------------------------------------------------------

Interaction of recombinant CbpM protein with plasma proteins was evaluated using Western blot and the results showed that this recombinant protein as well as ScaA protein (positive control) has positive reaction with fibronectin and fibrinogen proteins ([Fig. 5](#F5){ref-type="fig"} and [6](#F6){ref-type="fig"}).

![Analysis of interaction between CbpM and fibrinogen proteins. Lane M: stained protein marker (Takapozist, Iran); Spr1754 (36KDa) and ScaA (32KDa) proteins are negative and positive controls, respectively. CbpM has positive interaction with fibrinogen](IJPH-45-1610-g005){#F5}

![Analysis of interaction between CbpM and Fibronectin proteins. Lane M: stained protein marker (Takapozist, Iran); Spr1754 (36KDa) and ScaA (32KDa) proteins are negative and positive controls, respectively. CbpM has positive interaction with fibronectin](IJPH-45-1610-g006){#F6}

Reactivity of recombinant CbpM protein with serum antibody from pneumococcal patients
-------------------------------------------------------------------------------------

The ELISA results showed that seropositive rate for CbpM antigen was 100% among pneumococcal patients ([Fig. 7](#F7){ref-type="fig"}). The ELISA cut-off value was calculated as the mean +2SD of OD values from control sera, which was 0.004 and so the serum with OD≥ 0.004 considered as positive sera.

![Anti-CbpM titers in patients' sera with pneumococcal infection. S1toS10 represent patient's sera. Control groups are sera obtained from healthy individuals](IJPH-45-1610-g007){#F7}

Discussion
==========

Choline binding proteins are unique surface-exposed proteins in *S. pneumoniae* that contribute to many physiological functions. In silico analysis of CbpM with 129 amino acid sequence, shows that it is composed of four different domains. Two CW repeats (cell wall binding repeats) each 20 amino acid residues long located in the middle of protein. These repeats are characterized by conserved aromatic and glycine residues found in multiple tandem copies in a number of proteins ([@B15]). These repeats are responsible for the specific recognition of choline-containing cell walls in Streptococcus phage Cp-1. The second domain is a region of about 63 amino acids composed of three shorter repeats. These repeats bind with the cell wall because they are choline-binding proteins. The last region is YG repeats that seems to be a Glucan-binding domain. Regarding these information, CbpM lacks a CHAP (cysteine, histidine-dependent amidohydrolase/peptidase) domain, which is associated with many functions mainly in peptidoglycan amidases ([@B16]).

A major focus of this study was to determine whether CbpM reacts with the sera obtained from pneumococcal patients and binds to fibrinogen and fibronectin as plasma proteins. As indicated in the results section, CbpM showed a binding activity to fibronectin and fibrinogen. These data were consistent with other publications, which evaluated other surface-exposed proteins of gram-positive bacteria ([@B17]). The molecular interaction between plasma proteins and streptococci has been recognized from long time ago. The main purpose of such studies has been the principle that pathogenic streptococci bind to some plasma proteins, especially fibrinogen. There are some publications about bacterial fibrinogen binding proteins. However, most of these studies have focused on bacterial proteins other than pneumococcal proteins. Shannon et al showed that *Staphylococcus aureus* produces an extracellular fibrinogen binding protein, which binds to platelets and inhibits platelet aggregation. This interaction is a function of Efb binding to fibrinogen, which is naturally found on the surface of activated platelets ([@B18]).

In the present study, CbpM also showed a binding property to fibronectin. This is an abundant glycoprotein found in human serum and extracellular matrix, which is involved in cell adhesion processes. Fibronectin binding ability is a cardinal property of streptococci and involved in streptococcal attachment to epithelial cells ([@B19]). This protein was also associated with the invasion to human epithelial cells by group A streptococci ([@B20]). To date, two Fibronectin-binding proteins, PavA and SP0082 have been characterized in *S. pneumoniae* strain TIGR4 ([@B21]). PavA is one of the pneumococcal adhesions for fibronectin; however, Holmes et al. reported that 50% of fibronectin-binding activity is mediated by PavA protein and this activity remains even in pneumococcal PavA-mutants ([@B22]), the fact suggesting the presence of another fibronectin-binding molecule such CbpM protein on *S. pneumoniae*. Although there are limited literatures about pneumococcal CBPs interaction with fibronectin, however other plasma protein interactions with pneumococcal surface-exposed proteins were also studied. It has been shown that *S. pneumoniae* adheres and invades host cells through the integrin route by recruitment of a multimeric form of vitronectin ([@B23]). Bergmann et al. studied the interaction between pneumococci and vitronectin, and found that this property is lost following proteolytic treatment of the bacterial surface, a fact suggesting the proteinaceous nature of vitronectin-binding factor ([@B24]). In line with these findings, elimination of choline-binding proteins from the pneumococcal surface causes decreased interaction between vitronectin and the bacterium ([@B23]).

However, other factors may be involved in binding of plasma proteins to pneumococcal surface antigens. CbpM interacts with CRP and weakly binds to elastin in a dose-response state ([@B13]). From a bioinformatics point of view, CbpM is associated with pneumococcal choline binding proteins and is considered to be a surface-exposed protein. Due to lack of a LPXTG motif, it seems that CbpM is anchored to cell wall with ionic bond ([@B25]).

In the present study, CbpM reacted with sera obtained from patients with pneumococcal infections but not normal subjects, the fact that suggests it as a novel pneumococcal vaccine candidate, although a comprehensive study would be needed to reveal its nature.

Conclusion
==========

CbpM showed positive reaction in interaction with plasma proteins and patients sera. Considering the results of this study and bioinformatic analysis, CbpM seems to be involved in pneumococcal attachment to epithelial cells via glucan binding activity. Hence, this recombinant protein needs more evaluation from immunological point of views.
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